Display options
Cite
Yasmeen S, Hannan A, Sheikh F, et al. Borderline tumors of the ovary: A clinicopathological study. Pak J Med Sci. 2017;33(2):369-373doi: 10.12669/pjms.332.11847.
Yasmeen, S., Hannan, A., Sheikh, F., Syed, A. A., & Siddiqui, N. (2017). Borderline tumors of the ovary: A clinicopathological study. Pakistan journal of medical sciences, 33(2), 369-373. https://doi.org/10.12669/pjms.332.11847
Yasmeen, Samia, et al. "Borderline tumors of the ovary: A clinicopathological study." Pakistan journal of medical sciences vol. 33,2 (2017): 369-373. doi: https://doi.org/10.12669/pjms.332.11847
Yasmeen S, Hannan A, Sheikh F, Syed AA, Siddiqui N. Borderline tumors of the ovary: A clinicopathological study. Pak J Med Sci. 2017 Mar-Apr;33(2):369-373. doi: 10.12669/pjms.332.11847. PMID: 28523039; PMCID: PMC5432706.
Copy Download .nbib Format: NLM
Share it on

Pak J Med Sci. 2017 Mar-Apr;33(2):369-373. doi: 10.12669/pjms.332.11847.

Borderline tumors of the ovary: A clinicopathological study.

Pakistan journal of medical sciences

Samia Yasmeen, Abdul Hannan, Fareeha Sheikh, Amir Ali Syed, Neelam Siddiqui

Affiliations

  1. Dr. Samia Yasmeen, MBBS, FCPS (Medicine), Fellow Medical Oncology, Dept. of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital & Research Centre, 7-A block, R-3 Johar Town, Lahore, Pakistan.
  2. Dr. Abdul Hannan, MBBS, MD, FCPS (Medicine), FCPS (Medical Oncology), Resident Internal Medicine, East Tennessee State University Department of Internal Medicine, Johnson City, Tennessee Johnson City, USA.
  3. Dr. Fareeha Sheikh, MBBS, FCPS(Medicine), Fellow Medical Oncology, Dept. of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital & Research Centre, 7-A block, R-3 Johar Town, Lahore, Pakistan.
  4. Dr. Amir Ali Syed, MBBS, FRCS, Consultant Surgical Oncologist, Dept. of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital & Research Centre, 7-A block, R-3 Johar Town, Lahore, Pakistan.
  5. Dr. Neelam Siddiqui, MBBS, FRCP, CCST (Medical Oncology), Consultant medical Oncologist, Dept. of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital & Research Centre, 7-A block, R-3 Johar Town, Lahore, Pakistan.

PMID: 28523039 PMCID: PMC5432706 DOI: 10.12669/pjms.332.11847

Abstract

OBJECTIVE: To report experience with borderline ovarian tumors (BOTs) in a developing country like Pakistan with limited resources and weak database of health system.

METHODS: Patients with BOTs managed at Shaukat Khanum Cancer hospital, Lahore, Pakistan from 2004 to 2014 were included and reviewed retrospectively. Data was recorded on histopathological types, age, CA-125, stage of disease, treatment modalities and outcomes.

RESULTS: Eighty-six patients with BOT were included with a median age of 35 years. Forty-two (49%) patients had serous BOTs and 43 (50%) had mucinous BOTs, while one (1%) had mixed type. Using FIGO staging, 80 patients had stage I; two patients had IIA, IIB and stage III each. Median follow-up time was 31.5 months. All patients had primary surgery. Seventy (81%) patients underwent complete surgical resection of tumor. Forty-three (50%) patients had fertility preserving surgery. Seventy-three (85%) patients remained in remission. Recurrent disease was observed in 13 (15%) patients. Median time to recurrence was 22 months. On further analysis, age above forty years, late stage at diagnosis and incomplete surgery were significantly associated with invasive recurrence.

CONCLUSION: Despite a low malignant potential, relapses may occur in patients above forty years of age, incomplete surgery and staging information and advanced stage at presentation. Fertility sparing surgery should be considered in young patients. Complete excision of tumor and prolonged follow-up are advised because recurrence and transformation to invasive carcinoma may occur.

Keywords: Borderline ovarian tumor; FIGO; Mucinous ovarian tumor; Serous ovarian tumor

Conflict of interest statement

Declaration of interest: Authors do not have any conflict of interest in the publication of this article.

References

  1. Ann Oncol. 2016 Apr;27 Suppl 1:i20-i22 - PubMed
  2. Obstet Gynecol Sci. 2015 May;58(3):183-7 - PubMed
  3. J Clin Oncol. 2001 May 15;19(10):2658-64 - PubMed
  4. Ann Oncol. 2014 Jul;25(7):1320-7 - PubMed
  5. Fertil Steril. 2007 Aug;88(2):479-84 - PubMed
  6. Oncol Lett. 2015 Feb;9(2):912-914 - PubMed
  7. World J Surg Oncol. 2013 Jan 23;11:13 - PubMed
  8. Ann Oncol. 2010 Jan;21(1):55-60 - PubMed
  9. Am J Surg Pathol. 2010 Mar;34(3):433-43 - PubMed
  10. Eur J Cancer. 2013 May;49(8):1905-14 - PubMed
  11. Oncologist. 2015 Feb;20(2):151-8 - PubMed
  12. Obstet Gynecol. 1985 Sep;66(3):417-22 - PubMed
  13. Hum Reprod. 2011 Aug;26(8):2008-14 - PubMed
  14. Eur J Cancer. 2015 Mar;51(5):620-31 - PubMed
  15. Obstet Gynecol Sci. 2015 Mar;58(2):98-105 - PubMed
  16. Obstet Gynecol. 2000 Apr;95(4):541-7 - PubMed
  17. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S5-8 - PubMed
  18. Eur J Obstet Gynecol Reprod Biol. 2015 Jan;184:38-42 - PubMed
  19. J Gynecol Oncol. 2013 Jan;24(1):44-51 - PubMed
  20. Acta Obstet Gynecol Scand. 2016 Apr;95(4):473-9 - PubMed
  21. Zhonghua Fu Chan Ke Za Zhi. 2014 Apr;49(4):254-9 - PubMed
  22. Vopr Onkol. 2014;60(3):267-73 - PubMed

Publication Types